Replies to post #209434 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Significant Findings Revealed.

Got to listen to Dr. Missling’s presentation.

https://www.anavex.com/wp-content/uploads/2019/09/Janney-Audio-Presentation-Sept-2019.mp3

Lots of information; but the very best, I think is between 17:58 and 21:17, when Missling reveals that the Australian Alzheimer’s patients on the high dose of Anavex 2-73 for 57 weeks had improved scores of activities of daily living.

At three years (148 seeks), “activities of daily living almost not declining....” The plot line is almost flat. Cognition, too, continues during the period without notable decline.

Simply, then, Anavex 2-73, at the right dosage, essentially stops the progression of mental decline caused by Alzheimer’s disease, at least for three years.

Compare that to the results of Aricept (donepezil), the preferred FDA-approved Alzheimer’s disease treatment drug. It merely slows the progression of the disease, and only for a period, often just for a few months. Debility and death universally ensue.

Aricept is the standard of care (SOC). The Australian Alzheimer’s patients taking proper dosages of Anavex 2-73 have had, for three years, their disease effectively treated. No significant decline; continued normal cognition, etc.

If you were an official of the Australian drug approval agency, would you consider approving the drug for Australians being diagnosed with Alzheimer’s?

Is there any question that Anavex 2-73 is an efficacious Alzheimer's treatment drug?

[Investor2014]

Listened and was glad to hear Misslings PM description.

He is not saying that the WT vs variant Sigma-1 gene findings are to select patients thereby increasing chance of success. Instead the highly stat sig finding is another clear confirmation that the Sigma-1 MOA target is activated for efficacy by a2-73.

This along with the RNA expression confirmation adds some weight against the concern that the study was not placebo controlled.